Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72847 | 1.00 | CYP1A2 (0.55) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL22931544 | 0.85 | AHR (0.68) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL13790263 | 0.85 | AHR (0.68) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL13790273 | 0.85 | AHR (0.68) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL29507308 | 0.82 | AHR (0.65) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL9970464 | 0.80 | CYP1A2 (0.59) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL10031941 | 0.79 | AHR (0.57) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL5751953 | 0.78 | CYP1A2 (0.57) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL13267807 | 0.78 | CA1 (0.68) | CYP1A2AHRPTGS1FBP1NQO2 | |
| SCHEMBL28913499 | 0.77 | CYP1A2 (0.52) | CYP1A2AHRPTGS1FBP1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9045422-B2 | Piperidine derivatives with pesticidal properties | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-02 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5053070-A | PYRIMIDINE DERIVATIVES, PREPARATION PROCESSES THEREOF, HERBICIDE CONTAINING THE SAME, AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME ALONG WITH OTHER ACTIVE INGREDIENT | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4986846-A | PRE-AND POSTEMERGENCE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0374839-A1 | 2-(4,6-Dimethoxy-2-pyrimidinyloxy)benzaldoximes, preparation processes thereof, herbicides containing the same, and herbicidal compositions containing the same along with other active ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A2 135/4885AHR 1203/4885PTGS1 1542/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885AHR 1471/4885PTGS1 3838/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | CYP1A2 185/4885AHR 1235/4885PTGS1 899/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | CYP1A2 410/4885AHR 2237/4885PTGS1 1127/4885 |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | CYP1A2 479/4885AHR 2421/4885PTGS1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.